Pacira Pharmaceuticals, Inc. (PCRX)

Check out top investors' recommendation for PCRX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
85.00
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis and oncology, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Liana Moussatos Wedbush Securities Inc. Buy   Jun 25, '19     85.00  Jun 25, '20  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Mar 04, '19     85.00  Mar 04, '20  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Jan 29, '19     91.00  Jan 29, '20  N/A 
David Amsellem Piper Jaffray Buy   Jan 17, '19     55.00  Jan 17, '20  N/A 
David Amsellem Piper Jaffray Buy   Oct 09, '18     51.00  Oct 09, '19  N/A 
Randall Stanicky Canaccord Genuity Buy   Sep 19, '18     55.00  Sep 19, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Aug 06, '18     85.00  Aug 06, '19  N/A 
Serge Belanger Needham & Company Buy   Aug 03, '18     54.00  Aug 03, '19  N/A 
Douglas Tsao Barclays Buy   Aug 02, '18     50.00  Aug 02, '19  N/A 
Randall Stanicky Canaccord Genuity Buy   Aug 02, '18     50.00  Aug 02, '19  N/A 
Corey Davis Jefferies & Co. Buy   Aug 02, '18     53.00  Aug 02, '19  N/A 
Ken Trbovich C.K. Cooper & Company Sell   Jun 21, '18     27.00  Jun 21, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Jun 18, '18     80.00  Jun 18, '19  N/A 
David Amsellem Piper Jaffray Buy   Apr 09, '18     44.00  Apr 09, '19  N/A 
Corey Davis Jefferies & Co. Buy   Mar 20, '18     42.00  Mar 20, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Mar 07, '18     72.00  Mar 07, '19  N/A 
Randall Stanicky Canaccord Genuity Buy   Mar 01, '18     44.00  Mar 01, '19  N/A 
David Steinberg Deutsche Bank Securities Buy   Mar 01, '18     49.00  Mar 01, '19  N/A 
Douglas Tsao Barclays Buy   Feb 16, '18     40.00  Feb 16, '19  N/A 
David Amsellem Piper Jaffray Buy   Feb 07, '18     49.00  Feb 07, '19  N/A 
< previous123456